Brain Metastases, Adult Clinical Trial
Official title:
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.
This peri-operative window of opportunity study in patients with brain metastases will provide a single dose of the antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd, formerly U3-1402) prior to craniotomy to investigate pharmacokinetics, pharmacodynamics, intra- and peritumoral immune activation and responses, safety and explore potential biomarkers. This study will measure the level of the released payload DXd (MAAA-1181a) of patritumab deruxtecan, in resected brain metastasis (BrM) tissue. Patients will receive a single dose of patritumab deruxtecan intravenously before surgery. Patients will also have procedures such as medical history review, blood draws, MRI scans, ECGs, and lumbar punctures. The amount of time patients are expected to be in this study is approximately 40 days. Some of the risks of patritumab deruxtecan are diarrhea, nausea, vomiting, fatigue, headache, interstitial lung disease, and low blood counts. All participants who are administered patritumab deruxtecan as part of this peri-operative window of opportunity study will be included in analyses summarizing adverse events. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05428852 -
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
|
N/A | |
| Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
| Recruiting |
NCT05689619 -
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
|
N/A | |
| Recruiting |
NCT04197297 -
Brain Imaging Biomarkers in Patients With Brain Metastasis
|
Phase 2 | |
| Recruiting |
NCT04397978 -
Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
|
||
| Terminated |
NCT04434560 -
Neoadjuvant Immunotherapy in Brain Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT05095766 -
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
|
||
| Recruiting |
NCT05012254 -
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT05789589 -
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06280300 -
Multi-disciplinary Care for Brain Metastases
|
N/A | |
| Recruiting |
NCT06047379 -
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
Phase 1/Phase 2 | |
| Completed |
NCT03896555 -
Intrafractional Head Movement During Radiosurgery
|
||
| Terminated |
NCT03789149 -
Focal Intraoperative Radiotherapy of Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT04343157 -
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT04711824 -
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05793489 -
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
|
N/A | |
| Recruiting |
NCT04461418 -
Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT03818386 -
Radiotherapy of Multiple Brain Metastases Using AGuIX®
|
Phase 2 | |
| Active, not recruiting |
NCT05087095 -
Managing Distress in Malignant Brain Cancer
|
N/A | |
| Recruiting |
NCT04396717 -
Safety Study of Pritumumab in Brain Cancer
|
Phase 1 |